Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
LBL-034 (GPRC5D/CD3 BISPECIFIC T-CELL ENGAGER, TCE) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the "**Company**") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

The Company is pleased to announce that LBL-034 (GPRC5D/CD3 BsAb) was granted Fast Track Designation ("**FTD**") by the U.S. Food and Drug Administration ("**FDA**") for the treatment of relapsed/refractory multiple myeloma ("**RRMM**") on January 27, 2026.

ABOUT FTD

Pursuant to Section 112 of the Food and Drug Administration Modernization Act (the "**FDAMA**"), FTD is intended to facilitate the development and expedite the review of drugs and biologics that are intended to treat serious or life-threatening diseases that have the potential to address unmet medical needs.The granting of FTD provides a number of key incentives, including but not limited to: (1) more frequent interactions and guidance from the FDA, covering aspects such as clinical trial design and data requirements, which may help optimise the development pathway. In addition, a product granted FTD may be eligible for priority review of its marketing application or efficacy supplement, provided that clinical data are available to support such application; and (2) rolling review of marketing applications, allowing completed clinical data to be submitted to the FDA for review as they become available, prior to the completion of all required data, thereby potentially shortening the review timeline and expediting marketing approval.

ABOUT LBL-034

LBL-034 is a bispecific T-cell engager targeting both GPRC5D and CD3. By harnessing our proprietary CD3 T-cell engager platform – LeadsBody® platform, LBL-034 is designed with a 2:1 format, with two high-affinity Fabs targeting GPRC5D and one scFv targeting CD3. LBL-034 effectively redirects and activates T cells to target GPRC5D+ cancer cells, being less prone to inducing T cell exhaustion and cell death and minimizing the risk of cytokine release syndrome and immunotoxicity.

LBL-034 has demonstrated promising efficacy signals in both preclinical and clinical studies and is currently undergoing Phase I/II trials to evaluate its potential for treating malignant plasma cell neoplasms such as RRMM. Breakthrough clinical data on LBL-034 monotherapy for RRMM was presented in the opening oral presentation at the 2025 ASH conference. In October 2024, LBL-034 was granted the Orphan Drug Designation (ODD) by the FDA.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, LBL-034 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Nanjing, PRC, January 27, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Ni Jia as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive directors.